Skip to main content
رجوع
Watch Compare

NewAmsterdam Pharma Co N.V.

جودة البيانات: 100%
NAMSW
Nasdaq Manufacturing Chemicals
KWD 23.40
▼ KWD 0.10 (-0.43%)
القيمة السوقية: 2.78 B
السعر
KWD 23.50
القيمة السوقية
2.78 B
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—

Quick Summary

النقاط الرئيسية

Negative free cash flow of -147.78 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)-50.61%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-27.06%
أعلى من متوسط القطاع (-53.53%)
ROIC-23.67%
Net Margin-905.74%
Op. Margin-1002.90%

الأمان

Debt / Equity
N/A
Current Ratio12.57
Interest CoverageN/A

التقييم

PE (TTM)
-13.65
أقل من متوسط القطاع (-1.48)
P/B Ratio3.82
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1366 نظير)
المقياس السهم وسيط القطاع
P/E -13.7 -1.5
P/B 3.8 1.6
ROE % -27.1 -53.5
Net Margin % -905.7 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2027 — 135.80 M —
FY2026 — 21.71 M —

All Fundamental Metrics
Growth
Revenue Growth (1Y) -50.61% Revenue Growth (3Y) 26.38%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 22.50 M Net Income (TTM) -203.82 M
ROE -27.06% ROA -25.45%
Gross Margin N/A Operating Margin -1002.90%
Net Margin -905.74% Free Cash Flow (TTM) -147.78 M
ROIC -23.67% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 12.57
Interest Coverage N/A Asset Turnover 0.03
Working Capital 674.06 M Tangible Book Value 728.07 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -13.65 Forward P/E N/A
P/B Ratio 3.82 P/S Ratio 123.67
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -5.31%
Market Cap 2.78 B Enterprise Value 2.24 B
Per Share
EPS (Diluted TTM) -1.72 Revenue / Share 0.19
FCF / Share -1.25 OCF / Share -1.25
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 72.51%
SBC-Adj. FCF -201.18 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 22.50 M 45.56 M 14.09 M
Net Income -203.82 M -241.60 M -176.94 M
EPS (Diluted) -1.72 -2.56 -2.15
Gross Profit — — —
Operating Income -225.68 M -176.29 M -182.97 M
EBITDA — — —
R&D Expenses 141.83 M 151.41 M 159.42 M
SG&A Expenses 106.35 M 70.45 M 37.63 M
D&A 220,000.0 113,000.0 49,000.0
Interest Expense — 287,000.0 287,000.0
Income Tax -1,000.0 -1,000.0 27,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 769.28 M 864.62 M 347.10 M
Total Liabilities 85.85 M 107.12 M 58.70 M
Shareholders' Equity 683.43 M 757.50 M 288.39 M
Total Debt — — —
Cash & Equivalents 490.00 M 771.74 M —
Current Assets 675.70 M 863.41 M 346.79 M
Current Liabilities 85.79 M 106.92 M 49.90 M